已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Adjustable intragastric balloon for treatment of obesity: a multicentre, open-label, randomised clinical trial.

医学 减肥 耐受性 临床试验 随机对照试验 人口 肥胖 内科学 气球 外科 不利影响
作者
Barham K Abu Dayyeh,Daniel B Maselli,Babusai Rapaka,Thomas Lavin,Mark Noar,Hisham Hussan,Christopher G Chapman,Violeta Popov,Pichamol Jirapinyo,Andres Acosta,Eric J Vargas,Andrew C Storm,Fateh Bazerbachi,Marvin Ryou,Matthew French,Sabrena Noria,Daniel Molina,Christopher C Thompson
出处
期刊:The Lancet [Elsevier BV]
卷期号:398 (10315): 1965-1973 被引量:7
标识
DOI:10.1016/s0140-6736(21)02394-1
摘要

Intragastric balloons are anatomy-preserving, minimally invasive obesity therapies. Enhanced tolerance and durability could help broaden clinical adoption. We investigated the safety and efficacy of an adjustable intragastric balloon (aIGB) in adults with obesity.In this prospective, multicentre, open-label, randomised clinical trial done at seven US sites, adults aged 22-65 years with obesity were randomly assigned (2:1) to aIGB with lifestyle intervention or lifestyle intervention alone (control) for 32 weeks. Balloon volume could be increased to facilitate weight loss or decreased for tolerability. Coprimary endpoints included mean percentage total bodyweight loss and responder rate (≥5% total bodyweight loss) at 32 weeks. We used a multiple imputed intention-to-treat population analysis. This study was registered with ClinicalTrials.gov, NCT02812160.Between Aug 9, 2016, and Dec 7, 2018, we randomly assigned 288 patients to aIGB (n=187 [65%]) or control (n=101 [35%]) groups. Mean total bodyweight loss at 32 weeks was 15·0% (95% CI 13·9-16·1) in the aIGB group versus 3·3% (2·0-4·6) in the control group (p<0·0001). Clinical response was observed in 171 (92%) patients in the aIGB group. Adjustments to the aIGB occurred in 145 (80%) patients for weight loss plateau or intolerance. Upward volume adjustment facilitated an additional mean 5·2% (4·5-5·8) total bodyweight loss. Downward volume adjustment allowed 21 (75%) patients in the aIGB group to complete the full duration of therapy. Intolerance caused early removal of the device in 31 (17%) patients. No micronutrient deficiencies were observed in the aIGB cohort. Device-related serious adverse events were observed in seven (4%) patients, without any deaths.When aIGB was combined with lifestyle modification, significant weight loss was achieved and maintained for 6 months following removal. Balloon volume adjustability permitted individualised therapy, maximising weight loss and tolerance.Spatz Medical.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
啊的课件教案关注了科研通微信公众号
刚刚
4秒前
浮游应助七七采纳,获得10
5秒前
5秒前
yao关闭了yao文献求助
6秒前
FashionBoy应助anya采纳,获得200
7秒前
8秒前
萝卜青菜完成签到,获得积分10
9秒前
小李子关注了科研通微信公众号
11秒前
保卫时光发布了新的文献求助50
11秒前
眼中星光发布了新的文献求助10
13秒前
13秒前
13秒前
善学以致用应助百浪多息采纳,获得10
14秒前
张达发布了新的文献求助10
14秒前
15秒前
15秒前
捏捏我的小短腿完成签到,获得积分10
17秒前
RDF发布了新的文献求助10
17秒前
18秒前
18秒前
木木夕云发布了新的文献求助10
19秒前
zhizhi完成签到,获得积分20
19秒前
yinjs158发布了新的文献求助10
19秒前
上官若男应助张达采纳,获得10
20秒前
20秒前
21秒前
文静的刺猬完成签到,获得积分20
22秒前
777567发布了新的文献求助10
23秒前
YuuuY发布了新的文献求助10
23秒前
23秒前
24秒前
快乐石头发布了新的文献求助10
24秒前
sweetrumors发布了新的文献求助10
25秒前
wen发布了新的文献求助30
25秒前
柳易槐发布了新的文献求助20
25秒前
小李子发布了新的文献求助10
25秒前
26秒前
27秒前
高分求助中
Pipeline and riser loss of containment 2001 - 2020 (PARLOC 2020) 1000
哈工大泛函分析教案课件、“72小时速成泛函分析:从入门到入土.PDF”等 660
Comparing natural with chemical additive production 500
The Leucovorin Guide for Parents: Understanding Autism’s Folate 500
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 500
A Manual for the Identification of Plant Seeds and Fruits : Second revised edition 500
The Social Work Ethics Casebook: Cases and Commentary (revised 2nd ed.) 400
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 内科学 生物化学 物理 计算机科学 纳米技术 遗传学 基因 复合材料 化学工程 物理化学 病理 催化作用 免疫学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 5209090
求助须知:如何正确求助?哪些是违规求助? 4386405
关于积分的说明 13660783
捐赠科研通 4245503
什么是DOI,文献DOI怎么找? 2329333
邀请新用户注册赠送积分活动 1327184
关于科研通互助平台的介绍 1279467